Epilepsy Surgery Market Size was valued at USD 1.17 Billion in 2023. The Global Epilepsy Surgery industry is projected to grow from USD 1.24 Billion in 2024 to USD 1.94 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.89% during the forecast period (2024 - 2032).
Rising epilepsy prevalence and surgical procedure demand, increasing occurrences of brain damage brought on by traffic accidents, robot-assisted surgery development and. These are just a few of the market drivers that are driving the Epilepsy Surgery market.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Epilepsy is one of the most prevalent neurological illnesses worldwide, with an estimated 50 million individuals suffering from it, according to the WHO's fact sheets for 2019. People with epilepsy make up over 80% of the population in low- and middle-income nations. According to estimates, 70% of people with epilepsy might avoid seizures if their condition is adequately identified and treated. After a stroke, migraines, and Alzheimer's disease, epilepsy is the fourth most prevalent neurological condition. The US population's prevalence of active epilepsy was estimated at 1.2% (3.4 million) in 2015, according to the Centers for Disease Control and Prevention (CDC). At the University of Gondar Referral Hospital in Ethiopia, adult epileptic patients were evaluated in a research study published in 2018 on Sage Open Medicine. Seventy-nine adverse drug reactions were recorded, including exhaustion and gastrointestinal problems. Anticonvulsants, often antiepileptic medications, are a broad category of pharmaceuticals used to treat epileptic seizures.
Moreover, the growth in accidents and brain injuries, as well as the high rates of post-traumatic epilepsy (PTE) and post-traumatic seizure (PTS) incidence in patients with brain injuries, are the main factors propelling the epilepsy surgery industry. Thus, this factor is driving the Epilepsy Surgery market CAGR.
The epilepsy surgery market is being supported by the rising deployment of helper robots for precise and effective surgical planning & navigation. Due to much-reduced complication rates, better patient outcomes, and shorter operation times, patients choose minimally invasive epilepsy surgery. To treat epileptic diseases, epilepsy surgery involves stereo electroencephalography (SEEG), biopsy, thermal ablation of seizure foci or tumors, and deep brain stimulation (DBS). Additionally, computer-guided robotic arms derived from the automobile sector for neurosurgery applications were used before specialized stereotactic frameworks. To create a basic strategy for SEEG, neurologists and neurosurgeons work together under the direction of a noninvasive presurgical epilepsy workup. More than 150 recording locations may be available from a conventional montage of 10 electrodes. There have been few reports of robotic stereotactic aid in pediatric neurosurgery. Thus, it is anticipated that this aspect will accelerate the Epilepsy Surgery market revenue ly.
The Epilepsy Surgery market segmentation, based on Procedure type, includes Resective Surgery and Laser Interstitial Thermal Therapy (LITT)). The Laser Interstitial Thermal Therapy (LITT)segment held the majority share in 2022 in the Epilepsy Surgery market data. A minimally invasive method called LITT (Laser Interstitial Thermal Therapy) is used to treat drug-resistant epilepsy and seizures that don't respond to medication. Some persons with focal seizures—seizures that start in only one spot on the brain—may benefit from LITT. Three to four hours are typically needed for the LITT treatment. The advent of MRI-guided LITT devices has made it possible to ablate neurological soft tissue.
Figure 1 Epilepsy Surgery Market by Procedure type, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The Epilepsy Surgery market segmentation, based on End-user, includes Hospitals & Clinics and Specialty Centers. The Hospitals & Clinics segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This rise is mostly attributable to an increase in the number of persons getting epilepsy surgery and acquiring an epilepsy diagnosis. Because hospitals offer comprehensive and cutting-edge therapies, many choose to receive their care there. Patients with epilepsy are treated at clinics and other medical care facilities.
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Epilepsy Surgery market accounted for USD 0.50 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Due to various elements, including the availability of well-established healthcare facilities, the high prevalence of neurological illnesses, and the rising incidence of epilepsy, the Americas dominated the epilepsy surgery market. The US. and Canada are the major countries of North America. A central nervous system (CNS) illness, which produces seizures and is the fourth most prevalent neurological disease, is believed to affect approximately 150,000 Americans. The incidence rate is also highest in small children under two and individuals aged 65 and over. Epilepsy is becoming more common in the Americas. Seizures afflict around 300,000 Canadians, and one in every 2,000 persons is diagnosed with epilepsy yearly. In the Canadian population, neurological illnesses are also among the top causes of disability.
Further, the major countries studied in the Epilepsy Surgery market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 EPILEPSY SURGERY MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
With increasing investment in research & development, the production of successful epilepsy medications, and a high prevalence of epilepsy, Europe Epilepsy Surgery market has also evolved as a prominent market for epilepsy surgery. The region has considerable growth potential that would help with the expansion of the epilepsy surgery market in the coming years. According to the 2020 EU Industrial Research & Development Scoreboard, companies in the European Union have increased their investment in research & development. In 2019, European companies invested 5.6% more in R&D, compared to 4.7% in 2018. The production of successful medications to cure epilepsy in the region is increasing. Moreover, the UK Epilepsy Surgery market held the largest market share, and the Germany Epilepsy Surgery market was the fastest-growing market in the region.
The Asia-Pacific Epilepsy Surgery market offers lucrative opportunities for players, owing to a large senior population, governmental initiatives to improve the healthcare sector, increased research & development activities, and increased epilepsy incidence in the region. The prevalence of epilepsy in the elderly population is very high. It is estimated that the prevalence of epilepsy is 10.8 in 1,000. According to WHO, the population of the South-East Asia region is aging rapidly, and the proportion of people aged 60 or above was 9.7% in 2017. It is also estimated that the geriatric population will increase to 13.7% and 20.3% by 2030 and by 2050, respectively. Further, the China Epilepsy Surgery market held the largest market share, and the India Epilepsy Surgery market was the fastest-growing market in the region.
Epilepsy Surgery Key Market Players & Competitive Insights
Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for Epilepsy Surgery. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming more and more competitive, Epilepsy Surgery industry competitors must provide affordable products.
Manufacturing locally to cut operational costs is one of the main business methods producers use in the Epilepsy Surgery industry to benefit customers and increase the market sector. The Epilepsy Surgery industry has recently given medicine some of the most important advantages. In the Epilepsy Surgery market, major players such as Stryker (US), Zimmer Biomet Holdings Inc. (US), Auris Health Inc. (Hansen Medical Inc.) (US), Intuitive Surgical (US), Medtronic Plc (Mazor Robotics) (Ireland) In, Cephalon Inc (US), CMR Surgical (UK), Natus Medical Incorporated (US), Livanova Plc (UK), Monteris Medical (US) Company.
An American manufacturer of medical equipment is Medtronic plc. As a result of its acquisition of Covidien, an Irish corporation, the company has its operational and executive offices in Minneapolis, Minnesota, and its legal headquarters in Ireland. To treat medication-resistant epilepsy, Medtronic (Ireland) introduced its Deep Brain Stimulation system in the US in February 2019. For individuals with epilepsy who do not react to the medicine, the DBS offers a crucial surgical therapy alternative.
The da Vinci Surgical System is one of the robotic systems developed, produced, and marketed by Intuitive Surgical, Inc., an American company. These tools are intended to enhance clinical outcomes for patients through minimally invasive surgery. To create and distribute clinical video management and analytics tools for various surgical specialties, Intuitive Surgical (US) bought Orpheus Medical in February 2020. Intuitive Surgical can expand its integrated informatics platform thanks to this purchase.
Key Companies in the Epilepsy Surgery market include
Epilepsy Surgery Industry Developments
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.17 billion |
| Market Size 2024 | USD 1.24 billion |
| Market Size 2032 | USD 1.94 billion |
| Compound Annual Growth Rate (CAGR) | Â 5.89% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, End-User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â Stryker (US), Zimmer Biomet Holdings Inc. (US), Auris Health Inc. (Hansen Medical Inc.) (US), Â Intuitive Surgical (US), Medtronic Plc (Mazor Robotics) (Ireland), Cephalon Inc (US), CMR Surgical (UK), Natus Medical Incorporated (US), Livanova Plc (UK), Monteris Medical (US) Company |
| Key Market Opportunities | Collaboration with research institutes for market entrants to access markets |
| Key Market Dynamics | Increasing prevalence of epilepsy and demand for surgical procedures Rising number of cases of brain injuries due to road accidents Advancement and adoption of robot-assisted surgery |
Epilepsy Surgery Market Highlights:
Frequently Asked Questions (FAQ) :
The Epilepsy Surgery market size was valued at USD 1.17 Billion in 2023.
The Epilepsy Surgery market is projected to grow at a CAGR of 5.89% during the forecast period, 2024-2032.
North America had the largest share of the Epilepsy Surgery market
The key players in the Epilepsy Surgery market are Stryker (US), Zimmer Biomet Holdings Inc. (US), Auris Health Inc. (Hansen Medical Inc.) (US), Intuitive Surgical (US), Medtronic Plc (Mazor Robotics) (Ireland), Cephalon Inc (US), CMR Surgical (UK), Natus Medical Incorporated (US), Livanova Plc (UK), Monteris Medical (US) Company.
The LITT category dominated the Epilepsy Surgery market in 2022.
The Hospitals & clinics had the largest share of the Epilepsy Surgery market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
